INT60032

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1993
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 29
Total Number 30
Disease Relevance 12.42
Pain Relevance 5.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Pla2g2a) extracellular space (Pla2g2a) endoplasmic reticulum (Pla2g2a)
Anatomy Link Frequency
body 2
necks 1
spinal cord 1
paw 1
platelet 1
Pla2g2a (Mus musculus)
Pain Link Frequency Relevance Heat
metalloproteinase 29 100.00 Very High Very High Very High
diclofenac 380 99.88 Very High Very High Very High
Potency 3 99.00 Very High Very High Very High
Pain 28 98.84 Very High Very High Very High
Inflammation 117 98.80 Very High Very High Very High
Paracetamol 13 98.12 Very High Very High Very High
Spinal sensitization 2 97.80 Very High Very High Very High
cINOD 26 96.60 Very High Very High Very High
Spinal cord 34 96.16 Very High Very High Very High
Nerve growth factor 7 94.88 High High
Disease Link Frequency Relevance Heat
Parkinson's Disease 20 99.84 Very High Very High Very High
Hypersensitivity 418 99.50 Very High Very High Very High
Nociception 6 99.04 Very High Very High Very High
Pain 30 98.84 Very High Very High Very High
INFLAMMATION 149 98.80 Very High Very High Very High
Disease 38 98.64 Very High Very High Very High
Aspergillus Infection 12 98.28 Very High Very High Very High
Sprains And Strains 83 98.04 Very High Very High Very High
Drug Induced Neurotoxicity 4 97.80 Very High Very High Very High
Pancreatic Cancer 52 97.48 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The most active interacting compound 3h from in vitro inhibition of PLA2 activity showed similar potency in the in vivo neutralization of PLA2 induced mouse paw edema and hemolytic activity.
Negative_regulation (inhibition) of PLA2 in paw associated with pressure and volume under development and potency
1) Confidence 0.58 Published 2009 Journal Chem. Pharm. Bull. Section Abstract Doc Link 19122311 Disease Relevance 0.31 Pain Relevance 0.20
On the other hand, quinacrine inhibited PLA2 activity, and we propose here that the anti-angiogenic effect occurs via inhibition of the enzyme PLA2.
Negative_regulation (inhibited) of PLA2
2) Confidence 0.57 Published 2002 Journal Biol. Res. Section Abstract Doc Link 12462986 Disease Relevance 0.23 Pain Relevance 0.15
On the other hand, quinacrine inhibited PLA2 activity, and we propose here that the anti-angiogenic effect occurs via inhibition of the enzyme PLA2.
Negative_regulation (inhibition) of PLA2
3) Confidence 0.57 Published 2002 Journal Biol. Res. Section Abstract Doc Link 12462986 Disease Relevance 0.22 Pain Relevance 0.15
When injected subcutaneously into the necks of mice, histamine caused bouts of scratching, which were greatly reduced by pretreatment with capsazepine, a TRPV1 blocker, and by inhibitors of PLA2, LO, and H1R.
Negative_regulation (inhibitors) of PLA2 in necks
4) Confidence 0.48 Published 2007 Journal J. Neurosci. Section Abstract Doc Link 17329430 Disease Relevance 0.18 Pain Relevance 0.06
The fraction also showed weak inhibition of phospholipase A2 (PLA2) in-vitro.
Negative_regulation (inhibition) of PLA2
5) Confidence 0.46 Published 1997 Journal J. Pharm. Pharmacol. Section Abstract Doc Link 9231356 Disease Relevance 0.62 Pain Relevance 0.23
The substituent at the aroyl ring was responsible for enhancing the inhibition towards PLA2 enzymes.
Negative_regulation (inhibition) of PLA2
6) Confidence 0.43 Published 2009 Journal Chem. Pharm. Bull. Section Abstract Doc Link 19122311 Disease Relevance 0.31 Pain Relevance 0.11
Most of the newly synthesized compounds inhibit the purified PLA2 enzyme, and the inhibition was more in hydrophobic and aromatic substituents and less when no such substituents were present.
Negative_regulation (inhibit) of PLA2
7) Confidence 0.43 Published 2009 Journal Chem. Pharm. Bull. Section Abstract Doc Link 19122311 Disease Relevance 0.31 Pain Relevance 0.11
However, further studies are warranted to explore the therapeutic potential of PLA2 inhibitors for the treatment of Parkinson's disease.
Negative_regulation (inhibitors) of PLA2 associated with disease
8) Confidence 0.40 Published 2001 Journal Brain Res. Bull. Section Abstract Doc Link 11226716 Disease Relevance 0.93 Pain Relevance 0.22
In this investigation an attempt was made to determine a possible protective effect of quinacrine (QNC), a PLA2 inhibitor on MPTP as well as 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in rodents.
Spec (possible) Negative_regulation (inhibitor) of PLA2 associated with parkinson's disease and drug induced neurotoxicity
9) Confidence 0.40 Published 2001 Journal Brain Res. Bull. Section Abstract Doc Link 11226716 Disease Relevance 0.77 Pain Relevance 0.10
In vitro it potently inhibits phospholipase A2 (PLA2) [12], the enzyme which liberates arachidonic acid and lysophospholipid to generate a family of pro-inflammatory eicosanoids (including PGE2) and platelet activating factor.
Negative_regulation (inhibits) of PLA2 in platelet associated with inflammation
10) Confidence 0.39 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2939880 Disease Relevance 1.33 Pain Relevance 0.67
In addition to its inhibition of cyclooxygenases (COX), diclofenac potently inhibits phospholipase A2 (PLA2), thus yielding a broad anti-inflammatory effect.
Negative_regulation (inhibits) of PLA2 associated with inflammation and diclofenac
11) Confidence 0.39 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2939880 Disease Relevance 0.81 Pain Relevance 0.44
Pretreatment of mice with the phospholipase A2 (PLA2) inhibitors chlorpromazine or diltiazem one hour prior to APAP administration inhibits loss of mitochondrial Ca2+ homeostasis, prevents nuclear damage, and inhibits APAP hepatotoxicity as indicated by serum alanine aminotransferase activity and electron microscopic studies.
Negative_regulation (inhibitors) of PLA2 associated with paracetamol and hepatotoxicity
12) Confidence 0.35 Published 1993 Journal Res. Commun. Chem. Pathol. Pharmacol. Section Abstract Doc Link 8434130 Disease Relevance 0.17 Pain Relevance 0.99
For example, the cytosolic PLA2 inhibitor, AACOCF3, reduced both nociceptive sensitization and spinal arachidonic acid production in the spinal cord tissue of rats used in the chronic constriction injury model of neuropathic pain [34].
Negative_regulation (inhibitor) of PLA2 in spinal cord associated with nociception, eae, injury, neuropathic pain and spinal cord
13) Confidence 0.31 Published 2010 Journal Mol Pain Section Body Doc Link PMC2831877 Disease Relevance 0.71 Pain Relevance 0.75
Additional evidence suggests that diclofenac also inhibits PLA2 in vivo.
Negative_regulation (inhibits) of PLA2 associated with diclofenac
14) Confidence 0.29 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2939880 Disease Relevance 1.23 Pain Relevance 0.63
In light of diclofenac ability to inhibit potently both COX-2 and PLA2 we have explored its anticancer potential in a mouse model of pancreatic cancer.
Negative_regulation (inhibit) of PLA2 associated with pancreatic cancer and diclofenac
15) Confidence 0.29 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2939880 Disease Relevance 1.16 Pain Relevance 0.58
Accordingly, the mean PD50 causing a decrease in Cdyn, EF50 and GL to 50 % baseline was 0.4 ± 0.1 for GL, 0.4 ± 0.1 for Cdyn, and 1.2 ± 0.4 ?
Negative_regulation (decrease) of EF50
16) Confidence 0.10 Published 2005 Journal Respir Res Section Body Doc Link PMC1316879 Disease Relevance 0.30 Pain Relevance 0
In all cases, there was a predominance of metalloproteinases, BPPs, PLA2, serine proteinases and C-type lectins, with less abundant groups being LAO, CRISPs and growth factors (principally svVEGF and NGF).
Negative_regulation (predominance) of PLA2 associated with nerve growth factor and metalloproteinase
17) Confidence 0.10 Published 2010 Journal BMC Genomics Section Body Doc Link PMC3017861 Disease Relevance 0 Pain Relevance 0.22
A reduction in EF50 of more than 1.5 Standard deviation (SD) of mean baseline value (which translates to a reduction of more than 20% versus baseline) is considered to indicate airway constriction.
Negative_regulation (reduction) of EF50
18) Confidence 0.09 Published 2005 Journal Respir Res Section Body Doc Link PMC1316879 Disease Relevance 0 Pain Relevance 0
Invasive recordings of EAR in allergic mice showed significant decreases in simultaneously measured GL, Cdyn, and EF50 compared with controls thus indicating an allergen-specific EAR to A. fumigatus.
Negative_regulation (decreases) of EF50 associated with hypersensitivity
19) Confidence 0.09 Published 2005 Journal Respir Res Section Body Doc Link PMC1316879 Disease Relevance 0.32 Pain Relevance 0.06
It is also known that a decline in noninvasively measured EF50 is associated with an increase in TE [12,14].
Negative_regulation (decline) of EF50
20) Confidence 0.09 Published 2005 Journal Respir Res Section Body Doc Link PMC1316879 Disease Relevance 0.23 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox